Does dynamic post contrast MRI of the breast have a role in screening of high risk patients?  by Mokhtar, Omnia & Mahmoud, Sahar
The Egyptian Journal of Radiology and Nuclear Medicine (2014) 45, 1029–1041Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEDoes dynamic post contrast MRI of the breast
have a role in screening of high risk patients?* Corresponding author. Tel.: +20 1223236249.
E-mail address: omnian44@yahoo.com (O. Mokhtar).
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
0378-603X  2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2014.05.003Open access under CC BY-NC-ND license.Omnia Mokhtar *, Sahar MahmoudDepartment of Diagnostic Radiology, Cairo University, NCI, Benisuef, EgyptReceived 9 February 2014; accepted 5 May 2014
Available online 14 June 2014KEYWORDS
Dynamic post-contrast MRI;
High-risk breast cancer
patient;
Breast cancerAbstract Purpose: The aim of this work is to assess the role of dynamic post contrast MRI of the
breast as an adjunct to mammography in screening high risk women especially those with dense
breast parenchyma.
Patients and methods: A prospective study of 70 high risk cases of breast cancer who are examined
by mammography and MRM to evaluate the results.
Results: MRM proved higher sensitivity, speciﬁcity, positive and negative predictive values.
Conclusion: MRM proved to be of high importance in diagnosis and management of breast cancer.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
The key to surviving breast cancer, the second most common
cancer affecting female, is early detection and treatment (1).
Mammography has been proven to detect breast cancer at
an early stage and, when followed up with appropriate diagno-
sis and treatment, mammography was found to reduce mortal-
ity from breast cancer as well. For women at increased risk of
breast cancer, other screening technologies also may contrib-
ute to the earlier detection of breast cancer; particularly in
women under the age of 40 years for whom mammography
is less sensitive (2).
The American Cancer Society (ACS) guideline for the early
detection of breast cancer, last updated in 2003, stated thatwomen at increased risk of breast cancer might beneﬁt from
additional screening strategies beyond those offered to women
at average risk, such as earlier initiation of screening, shorter
screening intervals, or the addition of screening modalities such
as, breast ultrasound or magnetic resonance imaging (MRI)
other than mammography and physical examination (3).
Screening MRI is recommended for women with an approx-
imately 20–25% or greater lifetime risk of breast cancer, includ-
ing women with a strong family history of breast or ovarian
cancer and women who were treated for the Hodgkin disease.
There are more details to this, see ACR guidelines for MRI or
search net for women at average risk andwomen at high risk (4).
There are several risk subgroups for which the available
data are insufﬁcient to recommend for or against screening,
including women with a personal history of breast cancer, car-
cinoma in situ, atypical hyperplasia, and extremely dense
breasts on mammography. Several studies have demonstrated
the ability of MRI screening to detect cancer with early-stage
tumors that are associated with better outcomes (5).
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pared with mammography, and the types of cancers found
with MRI are the types that contribute to reduced mortality.
It is reasonable to extrapolate that detection of noninvasive
(DCIS) and small invasive cancers will lead to decreased mor-
bidity and mortality (1).Table 1 The parameters of the MRI study.
Parameters Protocol
TR 125 ms
TE 5.3 ms
Flip angle 60 (125/5.3/60)
Rectangular ﬁeld of view 37.0 · 37.0
Matrix 128 · 256
Slice thickness Small breasts – 2.0 mm+ no gap
Large breasts – 9.0 mm+ no gap2. Patients and methods
This study included 70 high risk patients. Their ages ranged
from 23 to 64 years with a mean age 45 years. Cases were
referred to the Radiology Departments of Kasr El Aini Hospi-
tal and Beni Sweif Faculty of Medicine from the General Sur-
gery Department and Oncology Outpatient clinics in the
period between December 2008 and March 2012.
2.1. The study group
The study group was classiﬁed according to their clinical pre-
sentations into two groups:
Group 1: Cases with a past history of breast carcinoma.
Group 2: High risk patients coming for regular annual
screening.
A thorough history was taken for each patient, focusing on,
the family history of breast carcinoma, menstrual history, con-
traceptive and hormonal intake history, previous history of
breast carcinoma, Prior breast imaging studies.
A clinical breast examination was performed for all patients
followed by routine digital mammography using the GE
Senographe 2000 Full Field digital mammography machine
(GE Senographe, Buc, Versaie, France). Two views were done
for each breast (craniocaudal and mediolateral) with spot com-
pression for selected case then Dynamic contrast enhanced
MRI study of the breast was performed using Philips, Gyro-
scan machine at 1.5 Tesla.
Pre-procedure preparation includes informing the patient
about the exam duration and the necessity to remain still to
minimize the motion artifacts and mis-registration errors
removing all ferromagnetic items (jewelry, watch, wallet, etc.)
and all upper body clothing were entirely removed
and replaced with a gown open to the front. The patient
was informed about the necessity of administrating the
contrast medium and possible contrast media intolerance
with the placement of an intravenous catheter for contrast
agent.
Breast MRI examination was performed with patients lying
in the prone position, with both breasts hanging freely in the
dedicated breast coil. Patients were asked to keep both arms
above their head, by their sides, or one in each position.
Image Acquisition Methods include coronal T1-weighted
spin echo sequence carried out for localization purposes, pre-
contrast T1WI fast spin echo (TR= 125 ms., TE = 5.3 ms.)
in the transverse orientation, T2-weighted fast spin echo
sequences (TR = 3740 ms., TE = 90 ms.) in the transverse
orientation, pre-contrast fat-saturated T2-weighted pulse
sequence to separate cysts from solid masses, Two- dimen-
sional T1-weighted gradient echo sequence with fat saturation
was then performed in the transverse orientation using the
parameters shown in Table 1.Then a bolus of gadopentetate dimeglumine (Gd-DTPA)
(Magnavist, Schering AC Berlin, Germany) was injected man-
ually (0.1 mmol/kg) in less than 10 s. Imaging was then
repeated using the aforementioned sequence (gradient echo
T1 weighted image with fat suppression) at the following time
points: one minute, 2 min., 4 min., 7 min., and sometimes
12 min guided by the visual assessment of the enhancement
patterns with thorough analysis of the pattern of enhancement
and proper selection of the region of interest (ROI) including
areas of highest contrast uptake.
The subtraction technique was used to highlight the
enhancing features in the image. It was performed between
the post contrast imaging and the pre contrast images in the
same axial plane using the software subtraction function avail-
able on the post processing workstation. Another useful post
processing tool is the maximum intensity projection (MIP).
Maximum intensity projection images were helpful for demon-
strating the distribution of disease in the breast in relation to
the skin, nipple, chest wall, and large vessels.
Mammographic ﬁndings were evaluated regarding breast
parenchymal density according to the ACR breast density clas-
siﬁcation: the presence of asymmetric density or parenchymal
distortion; mass lesion evaluated according to its outline (reg-
ular, irregular); its shape and form (well deﬁned, ill-deﬁned or
speculated); presence or absence of clustered microcalciﬁca-
tions; presence or absence of secondary signs as thickened skin,
retracted nipple, pathologically enlarged lymph nodes.
The ﬁndings of dynamic contrast enhanced MRM study
were evaluated regarding the pattern of enhancement: either
focus of enhancement (a single tiny punctate enhancement),
Non mass pattern: linear-ductal, linear-nonspeciﬁc, regional,
segmental, or diffuse or Mass enhancement.
The mass appearance was analyzed regarding Quantitative
and qualitative analysis of ﬁndings as mass number, Mass
form (round, oval, polygonal, linear, branching or speculated),
Mass margin (well deﬁned or indistinct), enhancing pattern
(homogenous, septated, inhomogeneous or ring pattern),
dynamics initial signal increase (<50%, 50–100%,>100%),
dynamics post initial course (steady increase, plateau or wash
out), extent of the lesions and the integrity of the chest wall
structures, presence of pathologically enlarged lymph nodes
and presence or absence of skin thickening.
Histopathological correlation using Trucut and/or exci-
sional biopsy was performed for 55 cases and results were cor-
related with MRM and mammographic ﬁndings.
3. Results
The study group included 70 high risk patients who were
divided into two groups:
Breast density of group1 
ACR 2 ACR 3 ACR 4
Fig. 1 The breast density according to the ACR classiﬁcation in
group 1.
Table 3 The correlation between mammography and pathol-
ogy results.
Diseased Normal Total test results
Positive (TP) 14 (FP) 16 30
Negative (FN) 6 (TN) 4 10
Total 20 20 40
Table 4 Statistical evaluation of mammographic ﬁndings in
group 1.
Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
PPV
(%)
NPV
(%)
Mammography 70 20 45 47 40
Role of dynamic post contrast MRI of the breast 10311. Group 1: Cases with history of breast carcinoma (40 cases,
57%).
2. Group 2: high risk patients coming for regular annual
screening (30 cases, 43%).
3.1. Statistical analysis of group 1
It included 40 (57%) cases with a past history of breast carci-
noma who underwent either conservative breast surgery (22
cases, 55%) or modiﬁed radical mastectomy (18 cases, 45%).
Their ages ranged between 30 and 64 years with a mean age
of 47 years. Regarding their family history; twelve cases
(30%) had positive family history (Table 2).
The mammographic ﬁndings of group 1 included breast
density that was categorized according to the ACR system into
(Fig. 1): cases with ACR 2 (2 cases/5%), ACR 3 (30 cases/
75%) and ACR 4 (8 cases/20%).
The mammographic ﬁndings were analyzed; parenchymal
distortion was detected in 25 cases (63%), mass lesions were
seen in 8 cases (20%) and no abnormality was deﬁned in the
remaining 10 cases (25%).
Mammographic diagnosis of group 1 according to the BIR-
ADS classiﬁcation system was, twelve cases (30%) were cate-
gorized as BIRADS 3 and 18 cases (45%) were categorized
as BIRADS 4. Ten cases (25%) showed no deﬁnite
abnormality.
Mammography ﬁndings were correlated with results of
pathology reports and accordingly the following results were
deduced as shown in Table 3.
The calculated sensitivity, speciﬁcity, accuracy, positive and
negative predictive values are listed in Table 4 and Fig. 2.
Dynamic MRM evaluation of group 1 showed twelve
(30%) cases showed no enhancement while 28 (70%) cases
showed contrast uptake according to the following patterns:
Non mass enhancement: 10 (25%) cases. Mass enhancement:
14 (35%) cases and Foci of enhancement in 4 (10%) cases
(Tables 5 and 6 and Fig. 3).
Evaluation of ﬁndings of post contrast MRM according to
the BIRADS classiﬁcation revealed eighteen cases were catego-
rized as BIRADS 2, Four cases were categorized as BIRADS
3, Eight cases were categorized as BIRADS 4 and Ten cases
were categorized as BIRADS 5.
MRM ﬁndings were correlated with results of clinical ﬁnd-
ings and pathology reports and accordingly the following
results were deduced as shown in Table 7.
For statistical evaluation of MRM ﬁndings in group 1, the
calculated sensitivity, speciﬁcity, accuracy, positive and nega-
tive predictive values are listed in Tables 8 and 9 and Figs. 4
and 5.Table 2 The operative and family history of group 1.
Count (Percentage)
Past history of
-Conservative surgery 22 (55%)
-MRM 18 (45%)
Family history of breast carcinoma
-Positive 12 (30%)
-Negative 28 (70%)
Fig. 2 Statistical evaluation of mammographic ﬁndings in group
1.3.2. Statistical analysis of group 2
This group included 30 high risk patients’ cases coming for
regular annual screening, Twenty-six cases (87%) gave positive
family history of breast carcinoma.
The mammographic ﬁndings of group 2 included breast
density that was categorized according to the ACR system into
Table 5 Patterns of enhancement in MRM in group 1.
Enhancement pattern Count (Percentage)
No enhancement 12 (30%)
Non mass enhancement 10 (25%)
Mass enhancement 14 (35%)
Focus of enhancement 4 (10%)
Total 40 (100%)
Fig. 3 Percentage of pattern of enhancement inMRM in group 1.
Table 8 Statistical evaluation of MRM ﬁndings in group 1.
Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
PPV
(%)
NPV
(%)
MRM 90 80 85 82 89
Table 7 The correlation between MRM ﬁndings with the
results of clinical ﬁndings and pathology reports, the following
results were deduced.
Diseased Normal Total test results
Positive (TP) 18 (FP) 4 22
Negative (FN) 2 (TN) 16 18
Total 20 20 40
Table 6 Evaluation of enhancement pattern of mass lesions
detected by dynamic post contrast MRM.
Criterion Count Percentage
Form -Oval, round 4 29
-Spiculated 10 71
Margin -Well deﬁned 4 29
-Indistinct 10 71
Enhancing pattern -Homogeneous 6 43
-Inhomogeneous 6 43
-Ring 2 14
Dynamics, initial
signal increase
-<50% 4 29
-50–100% 3 21
->100% 7 50
Dynamics post initial
signal increase
-Steady increase 2 14
-Plateau 5 36
-Wash out 7 50
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cases/83%) and ACR 4 (3 cases/10%).
The mammographic ﬁndings were analyzed as parenchymal
distortion was detected in 15 cases (50%), mass lesions were
seen in 10 cases (33%) and no abnormality was deﬁned in 10
cases (33%).
Mammographic diagnosis of group 2 according to the BIR-
ADS classiﬁcation system was, Nine (30%) cases were catego-
rized as BIRADS 3 and 11 (37%) cases were categorized as
BIRADS 4. Ten (33%) cases showed no deﬁnite abnormality.In correlation with the pathological results we found the
following data analyzed in Table 10:
For statistical evaluation of mammographic ﬁndings in
group 2 the calculated sensitivity, speciﬁcity, accuracy, positive
and negative predictive values are listed in Table 11.
Dynamic MRM evaluation of group2 included twelve
(40%) cases showed no enhancement while 18 (60%) cases
showed contrast uptake according to the following patterns:
Non mass enhancement: 2 (7%) cases. Mass enhancement:
14 (46%) cases and Foci of enhancement: 2 (7%) cases (Tables
12 and 13 and Fig. 8).
Evaluation of ﬁndings of post contrast MRM according to
the BIRADS classiﬁcation was ﬁfteen cases were categorized
as BIRADS 2, Two cases were categorized as BIRADS 3, eight
cases were categorized as BIRADS 4 and ﬁve cases were cate-
gorized as BIRADS 5.
In correlation with the clinical and pathological results we
found the following data analyzed in Table 14.
For statistical evaluation of MRM ﬁndings in group 2 the
calculated sensitivity, speciﬁcity, accuracy, positive and nega-
tive predictive values are listed in Tables 15 and 16 and Figs. 9
and 10.
4. Some illustrated cases are shown
4.1. Case 1
Clinical data: 27 year-old patient presenting with left axillary
tail palpable mass lesion.
4.1.1. Mammographic ﬁndings (Fig. 11A, B)
Bilateral mammography shows dense breast parenchyma ACR
3. There is a small sized asymmetric density in the left UOQ
with no evidence of speculated masses or clustered microcalci-
ﬁcations. It was categorized as BIRADS 3.
4.1.2. Dynamic MRI of the breast ﬁndings
Right breast (Fig. 11C, D, E, and F): Homogenously enhanc-
ing speculated mass lesion was seen in the central part at 2
o’clock. It appears of low T2 signal. The dynamic study
showed rapid contrast uptake and plateau curve patterns. It
was categorized as BIRADS 4.
The left breast (Fig. 11G): Another speculated mass lesion
was seen in the left axillary tail region. It showed inhomoge-
Table 9 Comparison between the statistical analysis of post contrast MRM and mammographic ﬁndings in group 1.
Sensitivity (%) Speciﬁcity (%) Accuracy (%) PPV (%) NPV (%)
Post contrast MRM 90 80 85 82 89
Mammographic ﬁndings 70 20 45 47 40
Fig. 4 Statistical evaluation of MRM ﬁndings in group 1.
Fig. 5 Comparison between the statistical analysis of MRM and
mammographic ﬁndings in group 1.
Fig. 6 The breast density according to the ACR classiﬁcation in
group 2.
Fig. 7 Statistical evaluation of mammographic ﬁndings in group
2.
Table 10 The pathological results of group 2.
Diseased Normal Total test results
Positive (TP) 9 (FP) 11 20
Negative (FN) 6 (TN) 4 10
Total 15 15 30
Role of dynamic post contrast MRI of the breast 1033neous contrast enhancement. Upon performing dynamic study
it showed a rapid rise and washout curve patterns. It was cat-
egorized as BIRADS 5.
4.1.3. Pathology
Bilateral malignant invasive ductal carcinoma: this pathologi-
cal diagnosis agreed with that of the MRM ﬁndings.
4.2. Case 2
Clinical data: 35 year-old patient with ﬁrst degree positive fam-
ily history of breast carcinoma. The patient with a history of
multicentric right breast invasive ductal carcinoma on neoad-
juvant chemotherapy presented to detect disease progress.
Table 11 Statistical evaluation of mammographic ﬁndings in group 2.
Sensitivity (%) Speciﬁcity (%) Accuracy (%) PPV (%) NPV (%)
Mammography
60 27 43 45 40
60 27 4 45 40
Table 12 Patterns of enhancement in MRM in group 2.
Enhancement pattern Count (Percentage)
No enhancement 12 (40%)
Non mass enhancement 2 (7%)
Mass enhancement 14 (46%)
Focus of enhancement 2 (7%)
Total 30 (100%)
Table 13 Evaluation of enhancement pattern of mass lesions
detected by dynamic post contrast MRM.
Criterion Count Percentage
Form -Oval, round 5 36
-Spiculated 9 64
Margin -Well deﬁned 5 36
-Indistinct 9 64
Enhancing pattern -Homogenous 6 43
-Inhomogenous 7 50
-Ring 1 7
Dynamics, initial
signal increase
-<50% 4 29
-50–100% 3 21
->100% 7 50
Dynamics post initial
signal increase
-Steady increase 2 14
-Plateau 5 36
-Wash out 7 50
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Inhomogeneous dense breast parenchyma (ACR 3). An area of
architectural distortion with spiculated outline is seen in the
right UOQ. It was categorized as BIRADS 4.
4.2.2. Dynamic MRI of the breast ﬁndings (Fig. 12A, B, C, D)
Multiple spiculated mass lesions are seen in the upper parts
and the axillary region of the right breast. The lesions show
inhomogenous enhancement with type III curve pattern upon
performing dynamic contrast study. The most posteriorly
located lesion shows extension of its enhancing spiculations
to the muscle capsule with no evidence of muscle inﬁltration
BIRADS 5 Fig. 12.
4.3. Follow up of case 2
4.3.1. Mammographic ﬁndings
Post chemotherapy revealed no appreciable changes of the
mammographic ﬁndings.
4.3.2. Dynamic MRI of the breast ﬁndings (Fig. 13A, B, C)
Post chemotherapy showed decreased size, number and extent
of the previously seen multicentric right breast masses. They
show type II curve pattern on follow up study (Fig. 13).
4.4. Case 3
4.4.1. Clinical data
31 year-old patient, with history of left breast conservative sur-
gery followed by chemotherapy. She has positive family
history.
4.4.2. Mammographic examination (Fig. 14A)
It shows architectural distortion at the left UOQ related to the
scar site. There was no evidence of mass lesions on mammo-
graphic basis. It was categorized as BIRADS 3.
4.4.3. Dynamic MRM (Fig. 14B, C, D)
Localized area of parenchymal distortion related to the scar
site with insigniﬁcant contrast uptake. Bilateral multiple well
deﬁned homogenously enhancing masses with type I curve pat-
tern. Benign looking axillary lymph nodes are seen in the left
axillary. It was categorized as BIRADS 2.
4.4.4. Pathology
Bilateral breast ﬁbroadenomas Fig. 14.
4.5. Case 4
4.5.1. Clinical data
44 year-old patient with history of right breast conservative
surgery.4.5.2. Mammographic ﬁndings
Localized area of parenchymal distortion is seen at the right
UOQ (operative bed), associated with thickened skin. It was
categorized as BIRADS 4.
4.5.3. Dynamic MRM (Fig. 15)
Right UOQ area of parenchymal distortion related to the scar
site. It shows low signal in both T1 and T2 images with central
area of ﬂuid signal. An area of fat entrapment is seen related to
the operative scar denoting a benign nature.
BIRADS 3, Post-operative sequel (Fig. 15).
4.6. Case 5
4.6.1. Clinical data
73 year old patient with history of right malignant lumpec-
tomy, presented for follow up.
4.6.2. Mammographic ﬁndings (Fig. 16A)
Breast density: ACR3 showing asymmetric right UIQ density
associated with parenchymal distortion and thickened skin.
It was categorized as BIRADS 4.
Fig. 8 Percentage of pattern of enhancement in MRM in
group 2.
Table 14 The correlation between clinical and pathological
results.
Diseased Normal Total test results
Positive (TP) 13 (FP) 2 15
Negative (FN) 2 (TN) 13 15
Total 15 15 30
Table 15 Statistical evaluation of MRM ﬁndings in group 2.
Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
PPV
(%)
NPV
(%)
MRM 87 87 87 87 87
Fig. 9 Statistical evaluation of MRM ﬁndings in group 2.
Fig. 10 Comparison between the statistical analysis of MRM
and mammographic ﬁndings in group 2.
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A well-deﬁned localized oblong shaped cystic collection seen in
the right UIQ related to the operative bed. It measures
33 · 16 mm in diameter. It shows thin peripheral rim enhance-
ment in post contrast study. BIRADS 2, localized post-opera-
tive seroma (Fig. 16).
5. Discussion
Mammography screening is widely regarded as the only pro-
ven method for early detection of breast cancer. Large popula-
tions can be screened at a relatively low cost. However,
mammography does not detect all breast cancers and in some
series the false negative rate is between 20% and 30%. Mam-
mography is limited in patients with dense breast tissue and
with certain types of tumors. One of the major limitations of
mammography is the overlap in the appearance of benign
and malignant lesions. Some of the abnormal breast densities
on mammograms are actually caused by superimposition ofTable 16 Comparison between the statistical analysis of post contr
Sensitivity (%) Speciﬁcity (
Post contrast MRM 87 87
Mammographic ﬁndings 60 27normal densities, not all patients with suspected densities on
mammography would have breast cancer (6).
Magnetic resonance imaging (MRI) is one of the most
promising technologies for breast cancer screening in high-risk
patients. Of all current modalities, MRI has been shown to
have the highest sensitivity for the detection of invasive cancer.
So MRMammography has evolved as a diagnostic adjunct for
many aspects of breast imaging, but the area where it is show-
ing the most beneﬁt is in high-risk patients. MR Mammogra-
phy can be beneﬁcial in terms of both patient management and
cost reduction for care as it impacts treatment in nearly 50% of
cases (7).ast MRM and mammographic ﬁndings in group 2.
%) Accuracy (%) PPV (%) NPV (%)
87 87 87
43 45 40
Fig. 11 (A) and (B) Mammographic MLO views of both breasts. (C) Subtracted image (D) Post contrast, (E) color coded image and (F)
time/relative signal intensity curve of the right breast lesion. (G) Post contrast image of the left breast axillary tail mass lesion.
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Fig. 12 (A) T2 fat suppressed, (B) T2 SE, (C) subtracted image and (D) Post contrast images show the right breast multicentric lesions.
(E) MLO mammographic view of the right breast showing the UOQ area of architectural distortion with spiculated outline.
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ing with MRI as an Adjunct to Mammography (2007) stressed
the value of MR mammography as a screening tool in speciﬁc
patient populations. To date, one of the most hotly debated
areas of MR imaging of breast disease has been related to
screening. Family history of breast cancer is a trait that will
place a patient at increased risk for breast cancer. Other poten-
tial clinical indications include patients with mammographic or
palpable lesions before excisional biopsy; patients with incon-
clusive mammographic abnormality (8).
The American Cancer Society (2013) recommends annual
screening using magnetic resonance imaging (MRI) in addition
to mammograms beginning at age 30 in high-risk women (life-
time risk approximately 20%-25% or greater) based on the
presence of mutations in the breast cancer susceptibility genes,
BRCA1 and BRCA2; strong family history of breast and/or
ovarian cancer suggestive of mutation carrier status; or prior
chest radiation therapy (e.g., for Hodgkin lymphoma).We conducted a prospective study of 70 high risk patients.
Our study included two groups: patients with history of breast
carcinoma and cases coming for regular annual screening espe-
cially those with inconclusive mammographic ﬁndings. A thor-
ough history was taken focusing on the family history of breast
carcinoma.
All our cases were evaluated by mammography and com-
plementary US study. Dynamic MRM imaging was per-
formed. Histopathological assessment was done for 55 cases
with detected mass or non mass enhancement to guide our
results and was used as the gold standard of reference. In the
remaining cases ﬁndings were benign so there was no need
for pathological conﬁrmation.
The main problem with mammography in the less than 50
age group is that the majority of women is premenopausal
and has increased breast density. This reduces the sensitivity
of mammography to detect breast cancer. It is estimated that
approximately 70% of women in the less than 50 age group
Fig. 13 (A) T2 SE, (B) Subtracted image and (C) Post contrast images show regressive course of the right breast lesions.
Fig. 14 (A) MLO mammographic view of the left breast shows the UOQ scar site. (B) and (C) Post contrast images showing bilateral
homogenously enhancing masses (arrows). (D) Time signal intensity curve showing type I curve pattern.
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undertaken in those at moderate or high risk from their family
history and it has been found that mammographic screening
detected only 50% of cancers (9).
Magnetic resonance imaging has demonstrated high sensi-
tivities for the detection of breast cancer irrespective of age
of the patient or the density of the breast parenchymal tissue.
Different studies reported sensitivities between 88% and 100%
with speciﬁcities ranging from 37% to 97% (10).There is increasing evidence from the trials of breast mag-
netic resonance imaging that women at high risk may beneﬁt
from this technique as sensitivity is not dependent on breast
density (11).
According to the ACR classiﬁcation of breast density
almost all our cases showed dense breast parenchyma. They
were categorized as ACR 3 and ACR 4 categories. Only 4 cases
showed ACR 2 category. We found that increased mammo-
graphic density acts as a limitation for proper diagnosis. The
Fig. 15 (A) T1SE, (B) T2 SE, (C) T2 fat suppression and (D) Post contrast images. Showing the area of parenchymal distortion, small
central area of ﬂuid signal showing bright T2 signal and focal fat entrapment.
Fig. 16 (A) CC mammographic view. (B) T1 SE image. (C) T2 SE, (D) Post contrast image, (E) Subtracted image showing right UIQ
post operative seroma.
Role of dynamic post contrast MRI of the breast 1039false negative and false positive rates in mammographic exam-
ination were 17% and 38% respectively. When we performed
dynamic MRM study for cases with dense mammograms;
the false negative rate decreased to 6% and the false positive
rate to 9%.
Mammography fails to reveal the full extent of many can-
cers, and it overlooks others entirely while the use of dynamicmagnetic resonance imaging (MRI), has shown almost 100%
sensitivity in several studies and these high values agree with
our results. In fact, MRI is capable of detecting cancers invis-
ible to physical examination, mammography, and ultrasonog-
raphy, and its 3D capabilities improve the accuracy of lesion
measurements. Although its cost and inability to depict micro-
calciﬁcations are among the drawbacks militating against the
1040 O. Mokhtar, S. Mahmouduse of MRI in routine breast-cancer screening, the modality
has found a secure place in breast imaging, and the indications
are expanding all the time (12).
MRI has proved valuable for locating clinically and mam-
mographically occult primary lesions, as shown by two studies
at the Memorial Sloan-Kettering Cancer Center in New York.
The full tumor extent and pectoral muscle invasion were evi-
denced by contrast enhancement and disruption of fat planes
(13).
In the current study we diagnosed three cases of DCIS.
They showed inconclusive mammographic ﬁndings. On per-
forming dynamic MRM examination we found areas of non
mass sector or regional patterns of enhancement. Cases were
pathologically conﬁrmed.
Typically DCIS is represented as a linear, branching,
clumped or regional pattern of enhancement and sometimes
as an ill deﬁned diffuse segment of enhancement. This picture
can be confused with benign ﬁbrocystic changes. In the Neu-
bauer series, unilateral segmental enhancement with a granular
dotted morphology was the hallmark of DCIS (14).
The sensitivity of mammography in our 30 cases coming for
regular annual screening was 60%, the speciﬁcity in this group
was 27% and accuracy rate was 43%. On the other hand, we
found that MRM sensitivity, speciﬁcity and accuracy rate were
87%. These values are higher than that of the Dutch and
Canadian studies which reported the sensitivity of MRI to
be 71% and 77% while mammography was 40% and 36%,
respectively, in asymptomatic high risk cohorts (11).
The speciﬁcity of mammography in cases coming for regu-
lar annual screening was relatively low in comparison to the
speciﬁcity of mammography reported in the screening pro-
grams. This is attributed to selection of our study group unlike
the studies which have evaluated screening mammography
programs that deal with larger number of population.
For cases who had history of breast carcinoma, the number
of cases were 40 patients with their ages ranging from 30 to
64 years. Our results showed that the sensitivity of mammogra-
phy was 70%, the speciﬁcity was 20%, the accuracy rate 45%,
the positive predictive value (PPV) 47% and the negative
predictive value (NPV) 40%. The statistical analysis of
dynamic MRM revealed sensitivity of 90%, speciﬁcity 80%,
accuracy rate 85%, PPV 82% and NPV 89%. This means that
MRM had better ability to conﬁrm the presence of malignant
disease.
MRM can detect full tumor extent, integrity of the chest
wall structures and multiplicity of the lesions. It is the most
accurate imaging modality to monitor tumor response to che-
motherapy. Although follow up of tumor behavior before and
after chemotherapy was not the aim of our work; however one
of our cases was pathologically proved as multicentric invasive
ductal carcinoma of the right breast. The patient was examined
twice to monitor tumor response to the chemotherapy and the
disease extent. Mammographic and dynamic MRM examina-
tions were done for her two months apart. Initially, mammo-
graphic examination showed only heterogeneous dense breast
parenchyma (ACR 3) and area of architectural distortion with
spiculated outline in the right UOQ. No appreciable changes
were seen in the follow up study. When performing dynamic
MRM examination, we found multicentric inhomogeneously
enhancing spiculated right breast mass lesions. They showed
decreased size, number and extent of the multicentric right
breast masses in follow up study.Although the current cost of MRI precludes its widespread
use in general populations, this imaging tool appears to
improve the detection of cancer in women at increased risk,
such as women with a recent diagnosis of breast cancer (15).
The overall statistical analysis of our research work showed
that the sensitivity, the speciﬁcity, accuracy rate, PPV and the
NPV of mammography were lower than those of dynamic post
contrast MRM. These ﬁndings denoted the ability of MRM to
conﬁrm or to exclude the presence of malignant breast lesions.
The absence of enhancement in our present study was
found to be a statistically signiﬁcant sign that indicates the
absence of malignancy. This agrees with the previous study
done by Herrinton (16).
The success of screening programs for breast cancer lies in
their ability to detect early cancer, before it has spread to
lymph nodes or metastasized to distant sites. Recent studies
provide support for the beneﬁt of detecting ductal carcinoma
in situ, since this tumor is likely to progress to invasive disease
if left untreated. In addition to early detection of in situ or
node-negative invasive disease in the contralateral breast,
MRI, if positive, can lead to simultaneous treatment of syn-
chronous cancers rather than multiple treatments on separate
occasions (15).
Another advantage of breast MR imaging is the accurate
detection of tumor extent before surgical planning. It has also
been recommended for preoperative staging of breast cancer,
especially for determining multifocality and multicentricity
(lesions involving more than one quadrant) as well as for
detection of bulky residual disease at the lumpectomy site in
order to allow directed re-excision (17).
In our study we used both quantitative and qualitative
methods for image analysis. We correlate our ﬁndings with
those of the BIRADS system. Only, one of our cases was diag-
nosed as BIRADS 5. This case was false positive. It showed
malignant criteria in dynamic MRM study while it was patho-
logically proved to be sclerosing adenosis.
Dynamic contrast-enhanced breast magnetic resonance
imaging (MRI) provides superior sensitivity to detect breast
cancer and, when used in the appropriate clinical setting, it
has become a useful adjunct to mammography. Overlap in
the MRI appearance of some benign and malignant diseases
limits the speciﬁcity of breast MRI. The false-positive ﬁndings
which result then prompt for additional imaging and/or biop-
sies for benign disease. So the American Cancer Society has
outlined recommendations for the use of breast MRI for
breast cancer screening and the American College of Radiol-
ogy practice guidelines including the indications for the perfor-
mance of breast MRI (8).
The following clinical scenarios, for which breast MRI is
indicated are: Preoperative evaluation of patients with newly
diagnosed breast cancer, evaluation of breast cancer patients
treated with neoadjuvant chemotherapy, evaluation of breast
cancer patients with positive surgical margins following breast
conservation therapy, evaluation of patients with metastatic
axillary lymphadenopathy and an unknown primary malig-
nancy, determination of silicone breast implant integrity,
breast cancer screening in high risk women, and the use of
breast MRI as a problem-solving tool for equivocal mammo-
graphic ﬁndings.
Magnetic resonance imaging (MRI) screening is also cost-
effective for very high-risk women, such as BRCA carriers,
and others at 20% or greater lifetime risk (18).
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beginning at age 30 years was identiﬁed as a clinically effective
approach to applying current guidelines, and was more cost-
effective in BRCA1 gene mutation carriers compared with
BRCA2 gene mutation carriers (19).
In our study we recommended that MRM examination
should always be performed in certain groups of patients.
These cases coming for regular annual screening are particu-
larly those with positive family history, cases with inconclusive
mammographic ﬁndings, and cases with history of breast car-
cinoma. Patients with dense mammograms are considered to
be one of the high risk groups especially cases with positive
family history or suspicious clinical condition. For cases with
history of breast carcinoma we found that dynamic MRM is
the best modality to follow the disease progress, the presence
of recurrences and/or residual at the operative bed.6. Conclusion
From the results of our study we can conclude that dense
breast parenchyma acts as a limitation for proper diagnosis
of breast lesions. Dynamic contrast enhanced MRM study
has an important role as an adjunct to mammography in high
risk groups.
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